1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Sanofi building
Sanofi's pact with Earendil is the latest in several with AI-focused firms

Who: Sanofi/Earendil Labs

What: Sanofi is acquiring global development and commercial rights to two bispecific antibodies for autoimmune and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Digital Technologies